Ionis Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• On July 29, 2026, Ionis Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release furnished with the 8‑K.
• The company reported results prepared in accordance with GAAP and also provided pro forma (non‑GAAP) results that exclude non‑cash compensation expense related to equity awards and the related tax effects.
• Ionis stated it presents the pro forma information to help users assess and compare historical performance and to project future operating results and cash flows.

Key Details

• Date of filing/press release: July 29, 2026.
• Reporting period: quarter ended June 30, 2026.
• Non‑GAAP adjustment: excludes non‑cash equity‑award compensation expense and related tax effects.
• Exhibit furnished with the 8‑K: Press Release (Exhibit 99.1).

Why It Matters

• Investors should note both GAAP and non‑GAAP figures: GAAP shows results including stock‑based compensation expense, while the company’s pro forma view removes that non‑cash item to highlight underlying operating performance.
• Comparing GAAP vs. the company’s adjusted results can affect metrics like operating income and margins; understanding the adjustment helps with trend analysis and forecasting.
• The press release is furnished with the 8‑K for review; no other material actions (e.g., leadership changes, mergers) were reported in this filing.